MENLO PARK, Calif. – February 9, 2012 – Auxogyn, Inc., a privately-held company advancing
women’s reproductive health, announced today that the Personalized Medicine World
Conference (PMWC) and Prescience International selected the Auxogyn as the ‘Most Promising
Company’ at PMWC2012 annual conference, held January 23-24, 2012.
“We are honored to be recognized by industry leaders and our peers as the most promising
company for PMWC2012,” said Lissa Goldenstein, president and chief executive officer of
Auxogyn. “We look forward to bringing the promise of personalized medicine to the field of
assisted reproduction through Eeva, our proprietary non-invasive system that provides objective
information on embryo viability to guide patient treatment paths.”
Auxogyn was chosen from a group of 31 companies by a group of industry leaders including
Paul Billings, M.D., chief medical officer, LIFE Technologies, Rowan Chapman, Ph.D., partner,
Mohr Davidow Ventures, Edgar Engleman, M.D., managing partner, Vivo Ventures and Drew
Senyei, M.D., managing director, Life Science Practice, Enterprise Partners, as well as
audience polling.
“Auxogyn stood out among the presenting companies for its revolutionary approach to
improving patient outcomes during in vitro fertilization (IVF) procedures and reproductive health
as a whole,” said Tal Behar, co-founder of the Personalized Medicine World Conference. “The
ability to provide quantitative information for selection of embryos during IVF procedures holds
unique promise for the millions suffering from infertility today. We expect novel products like
Eeva to play an increasingly significant role in delivering high-quality, cost-effective healthcare
in the years to come, and we extend our sincere congratulations to Auxogyn on this premier
award.”
To qualify for the Most Promising Company Award, a company must be privately-held and
working the areas of therapeutics, diagnostics or platform and information technologies.
Selection is based on how a company’s innovation is disruptive to current standard-of-care, both
in cost and effectiveness; strength of team and ability to execute; barriers to competition and
strength of intellectual property and expected financial returns for investors.
About Eeva™
Auxogyn’s non-invasive early embryo viability assessment (Eeva) system may improve assisted
reproduction outcomes by providing IVF clinicians and patients with objective information on
embryo viability. Eeva’s proprietary software automatically analyzes embryo development
against scientifically and clinically validated cell-division timing parameters. With Eeva’s
quantitative data on each embryo’s potential development, IVF clinics may be able to select the
best embryo(s) for transfer or optimize the treatment path for their patients undergoing IVF
procedures. Auxogyn is completing a multi-center, 150-patient clinical trial to validate the safety
and efficacy of Eeva, and plans to use the results of the study for regulatory filings in Europe
and the United States in 2012.
About Auxogyn
Auxogyn, Inc. is focused on advancing the field of reproductive health through its uniquely-combined
knowledge of early human developmental biology, advanced computer vision
technology and best clinical practices. The company’s first product, Early Embryo Viability
Assessment (Eeva), provides quantitative information regarding embryo development, to assist
IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures.
Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, TPG Biotech and
Merck Serono Ventures. For more information regarding Auxogyn please visit
www.auxogyn.com.
Contact:
Angela Bitting
For Auxogyn
(925) 202-6211
[email protected]